Eudaimonia Partners’s Bristol-Myers Squibb BMY Stock Holding History

Eudaimonia Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,270	Closed	-$422K	–	261
2023 Q3	$422K	Buy	7,270 +4	+0.1%	+$245	0.1%	192
2023 Q2	$465K	Sell	7,266 -2,424	-25%	-$163K	0.1%	196
2023 Q1	$672K	Buy	9,690 +200	+2%	+$14.1K	0.16%	141
2022 Q4	$683K	Sell	9,490 -323	-3%	-$24.4K	0.17%	139
2022 Q3	$698K	Sell	9,813 -4,396	-31%	-$319K	0.18%	128
2022 Q2	$1.09M	Sell	14,209 -2,047	-13%	-$156K	0.2%	128
2022 Q1	$1.19M	Buy	+16,256	New	+$1.09M	0.2%	130
2021 Q3	$972K	Sell	16,435 -1,949	-11%	-$128K	0.18%	146
2021 Q2	$1.23M	Buy	18,384 +1,802	+11%	+$118K	0.23%	116
2021 Q1	$1.05M	Buy	16,582 +479	+3%	+$29.8K	0.22%	114
2020 Q4	$998K	Buy	16,103 +99	+0.6%	+$6.09K	0.22%	109
2020 Q3	$965K	Buy	16,004 +1,959	+14%	+$118K	0.25%	100
2020 Q2	$825K	Sell	14,045 -331	-2%	-$19.8K	0.31%	84
2020 Q1	$801K	Buy	14,376 +205	+1%	+$12.5K	0.35%	76
2019 Q4	$909K	Buy	+14,171	New	+$812K	0.36%	76

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Eudaimonia Partners's BMY Position: Q4 2023 in Review

Eudaimonia Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 7,270 shares — an estimated $422K sold.

Eudaimonia Partners first reported a position in BMY in Q4 2019 and held it in 15 quarters. The position peaked at $1.23M in Q2 2021. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Eudaimonia Partners reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Eudaimonia Partners sold 7,270 Bristol-Myers Squibb shares in Q4 2023, an estimated $422K.
Eudaimonia Partners first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 15 quarters.
Eudaimonia Partners's Bristol-Myers Squibb position peaked at $1.23M in Q2 2021.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Eudaimonia Partners's 13F filing for Q4 2023, filed 8 Feb 2024.